Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 21 to 25 of 25 matches

Category 5 - DIAGNOSTIC IMAGING SERVICES

61628

61628 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Nov-2017
Schedule Fee Start Date:
14-Jan-2002

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61632

61632 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Nov-2017
Schedule Fee Start Date:
01-Jul-2011

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61640

61640 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Jul-2011
Schedule Fee Start Date:
14-Jan-2002

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (R)

Bulk bill incentive



Fee: $999.00 Benefit: 75% = $749.25 85% = $915.60

Category 5 - DIAGNOSTIC IMAGING SERVICES

61646

61646 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Jul-2011
Schedule Fee Start Date:
14-Jan-2002

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (R)

Bulk bill incentive



Fee: $999.00 Benefit: 75% = $749.25 85% = $915.60

Category 5 - DIAGNOSTIC IMAGING SERVICES

61647

61647 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-May-2018
Schedule Fee Start Date:
01-May-2018

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body 68Ga‑DOTA‑peptide PET study (including any associated computed tomography scans for anatomic localisation and attenuation correction), if:

(a) a gastro‑entero‑pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or

(b) both:

(i) a surgically amenable gastro‑entero‑pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and

(ii) the study is for excluding additional disease sites

(R)

Bulk bill incentive



Fee: $1,053.00 Benefit: 75% = $789.75 85% = $969.60

(See para IN.0.13, IN.0.19 of explanatory notes to this Category)

Results 21 to 25 of 25 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change